Home > Haematology > Tazemetostat provides objective responses in follicular lymphoma, epithelioid sarcoma

Tazemetostat provides objective responses in follicular lymphoma, epithelioid sarcoma


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
Lancet Oncology
Reuters Health - 26/10/2020 - Tazemetostat, an oral inhibitor of the EZH2 protein, provides objective responses in patients with relapsed or refractory follicular lymphoma and advanced epithelioid sarcoma. That's according to findings from two open-label, single-arm phase-2 trials published in The Lancet Oncology. Activating mutations of EZH2, an epigenetic regulator of B-cell proliferation, are present in approximately 20% of patients with follicular lymphoma. And over 90% of epithelioid sarcomas have lost expression of INI1, which leads to unopposed oncogenic activation of EZH2. In the first trial, Dr. Franck Morschhauser of Universite de Lille, in France, and colleagues at 38 clinics or hospitals in Europe and North America investigated the activity and safety of tazemetostat in 99 patients with relapsed or refractory follicular lymphoma with wild-type or mutated EZH2. The objective response rate, defined as the proportion of patients with a best ov...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on